Omar Al Ustwani Jawad Francis Paul K Wallace Julian Ambrus Jr Meir Wetzler
10.1016/j.leukres.2010.12.015
Leuk Res
2011 May;35(5):e35-6.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/21247634/
Autoimmune Diseases / prevention & control Myelodysplastic Syndromes / therapy T-Lymphocytes, Regulatory / pathology
Autoimmune Diseases / prevention & control Myelodysplastic Syndromes / therapy T-Lymphocytes, Regulatory / pathology Case Reports Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Adult Antimetabolites, Antineoplastic / therapeutic use Autoimmune Diseases / complications Autoimmune Diseases / pathology Azacitidine / therapeutic use Blood Cell Count Down-Regulation Humans Huntington Disease / complications Huntington Disease / diagnosis Huntington Disease / immunology Lupus Erythematosus, Systemic / complications Lupus Erythematosus, Systemic / immunology Lupus Erythematosus, Systemic / therapy Male Myelodysplastic Syndromes / complications Myelodysplastic Syndromes / immunology Myelodysplastic Syndromes / pathology T-Lymphocytes, Regulatory / immunology Antimetabolites, Antineoplastic Azacitidine
PMC3079022
21247634
Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells
2011